Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$55.06 - $69.99 $549,223 - $698,150
9,975 Added 6.53%
162,742 $9.13 Million
Q4 2023

Jan 30, 2024

BUY
$57.25 - $69.74 $1.36 Million - $1.66 Million
23,802 Added 18.46%
152,767 $9.19 Million
Q3 2023

Oct 25, 2023

BUY
$63.16 - $76.5 $7.56 Million - $9.15 Million
119,658 Added 1285.68%
128,965 $8.66 Million
Q2 2023

Aug 03, 2023

BUY
$46.28 - $75.01 $430,727 - $698,118
9,307 New
9,307 $642,000
Q3 2022

Oct 07, 2022

BUY
$38.15 - $57.1 $1.66 Million - $2.49 Million
43,561 Added 33.9%
172,049 $7.02 Million
Q2 2022

Aug 10, 2022

BUY
$33.54 - $55.0 $4.31 Million - $7.07 Million
128,488 New
128,488 $7.07 Million
Q1 2022

May 13, 2022

SELL
$31.02 - $48.18 $729,218 - $1.13 Million
-23,508 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $967,119 - $1.34 Million
23,508 New
23,508 $1.1 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.